EGFR and neoplasm: Nimotuzumab is an EGFR monoclonal antibody that blocks the epidermal growth factor receptor signaling pathway, inhibits tumor angiogenesis, and enhances radiosensitivity, thereby achieving a synergistic effect where the combined outcome surpasses the individual contributions (43).